NO2324360T3 - - Google Patents

Info

Publication number
NO2324360T3
NO2324360T3 NO09807153A NO09807153A NO2324360T3 NO 2324360 T3 NO2324360 T3 NO 2324360T3 NO 09807153 A NO09807153 A NO 09807153A NO 09807153 A NO09807153 A NO 09807153A NO 2324360 T3 NO2324360 T3 NO 2324360T3
Authority
NO
Norway
Application number
NO09807153A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41669607&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2324360(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2324360T3 publication Critical patent/NO2324360T3/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
    • A61B5/4064—Evaluating the brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO09807153A 2008-08-11 2009-08-11 NO2324360T3 (cs)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18855408P 2008-08-11 2008-08-11
US9762208P 2008-09-17 2008-09-17
US21872709P 2009-06-19 2009-06-19
PCT/US2009/053376 WO2010019553A2 (en) 2008-08-11 2009-08-11 Biomarker detection process and assay of neurological condition

Publications (1)

Publication Number Publication Date
NO2324360T3 true NO2324360T3 (cs) 2018-06-30

Family

ID=41669607

Family Applications (1)

Application Number Title Priority Date Filing Date
NO09807153A NO2324360T3 (cs) 2008-08-11 2009-08-11

Country Status (9)

Country Link
US (3) US20110143375A1 (cs)
EP (3) EP2324360B1 (cs)
JP (2) JP5781436B2 (cs)
AU (1) AU2009282117B2 (cs)
CA (1) CA2733990C (cs)
DK (1) DK2324360T3 (cs)
ES (1) ES2665245T3 (cs)
NO (1) NO2324360T3 (cs)
WO (1) WO2010019553A2 (cs)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
EP3358354B1 (en) 2008-01-18 2020-07-15 President and Fellows of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
NO2324360T3 (cs) 2008-08-11 2018-06-30
US9874573B2 (en) * 2008-10-02 2018-01-23 Gaia Medical Institute Health test for a broad spectrum of health problems
WO2010148391A2 (en) * 2009-06-19 2010-12-23 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
US20120202231A1 (en) * 2009-07-18 2012-08-09 Kevin Ka-Wang Wang Synergistic biomarker assay of neurological condition using s-100b
US20130022982A1 (en) 2009-09-14 2013-01-24 Kevin Ka-Wang Wang Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
ES2735530T3 (es) 2010-01-26 2019-12-19 Bioregency Inc Composiciones y métodos relacionados con la argininosuccinato sintetasa
US20130029362A1 (en) * 2010-04-01 2013-01-31 Andreas Jeromin Markers and assays for detection of neurotoxicity
WO2011160096A2 (en) * 2010-06-17 2011-12-22 Banyan Biomarkers, Inc. Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
MX361944B (es) 2010-07-23 2018-12-19 President And Fellows Of Harvard College Star Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales.
SG187582A1 (en) 2010-07-23 2013-03-28 Harvard College Methods of detecting diseases or conditions using phagocytic cells
EP2596353A4 (en) 2010-07-23 2014-01-15 Harvard College METHOD FOR DETECTING PRENATAL OR PREGNANT DISEASES OR SUFFERING
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
WO2012051519A2 (en) * 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
WO2012155134A2 (en) 2011-05-12 2012-11-15 The Johns Hopkins University Assay reagents for a neurogranin diagnostic kit
US20140370531A1 (en) * 2011-12-14 2014-12-18 University Of Rochester Method of diagnosing mild traumatic brain injury
HK1206425A1 (en) 2012-03-13 2016-01-08 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
WO2014145036A1 (en) * 2013-03-15 2014-09-18 The Trustees Of Princeton University Rapid and sensitive analyte measurement assay
CN104603289A (zh) 2012-06-15 2015-05-06 哈里·斯泰利 检测疾病或病状的方法
BR112014031414A2 (pt) 2012-06-15 2017-06-27 Stylli Harry métodos de detectar doenças ou condições utilizando células doentes circulantes
EP2965086A4 (en) 2013-03-09 2017-02-08 Harry Stylli Methods of detecting prostate cancer
US10494675B2 (en) 2013-03-09 2019-12-03 Cell Mdx, Llc Methods of detecting cancer
US20150141528A1 (en) * 2013-05-31 2015-05-21 Banyan Biomarkers, Inc. Neural specific s100b for biomarker assays and devices for detection of a neurological condition
JP6611710B2 (ja) * 2013-07-17 2019-11-27 ザ・ジョンズ・ホプキンス・ユニバーシティ 脳損傷の検出および転帰についてのマルチプロテインバイオマーカー測定法
AU2015243926A1 (en) * 2014-04-08 2016-11-24 The Research Foundation For The State University Of New York Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
EP3204778A2 (en) * 2014-10-06 2017-08-16 Université de Genève Markers and their use in brain injury
US20190010504A1 (en) * 2015-12-11 2019-01-10 Arizona Board Of Regents On Behalf Of Arizona State University Human alzheimer's disease and traumatic brain injury associated tau variants as biomarkers and methods of use thereof
US20180106800A1 (en) * 2016-10-03 2018-04-19 Abbott Laboratories Methods of assessing uch-l1 status in patient samples
US11078298B2 (en) 2016-10-28 2021-08-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
CA3052636A1 (en) * 2017-02-07 2018-08-16 Bioregency, Inc. S100.beta. and isoforms for detection of neurological conditions
US10345302B2 (en) * 2017-02-19 2019-07-09 Sheng-He Huang Circulating astrocytes and MFSD2A as biomarkers
US11016092B2 (en) 2017-03-23 2021-05-25 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
EP3602069A1 (en) * 2017-03-23 2020-02-05 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
AU2018250688B2 (en) 2017-04-15 2024-07-04 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
JP7080899B2 (ja) 2017-04-28 2022-06-06 アボット・ラボラトリーズ 同じヒト対象に由来する少なくとも２つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
AU2018272054B2 (en) 2017-05-25 2024-10-31 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
JP7269183B2 (ja) 2017-05-30 2023-05-08 アボット・ラボラトリーズ 心臓トロポニンｉを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法
WO2019010131A1 (en) 2017-07-03 2019-01-10 Abbott Laboratories IMPROVED METHODS FOR MEASURING CARBOXY TERMINATION HYDROLASE LEVELS OF UBIQUITIN L1 IN BLOOD
EP3655545B1 (en) 2017-07-18 2023-10-18 The Research Foundation for The State University of New York Biomarkers for intracranial aneurysm
AU2018378971B9 (en) * 2017-12-09 2025-04-17 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase l1 (UCH-L1)
WO2019112860A1 (en) * 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
AU2018395255B2 (en) 2017-12-29 2025-02-20 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
WO2019199865A1 (en) * 2018-04-10 2019-10-17 Quanterix Corporation Quantification of biomarkers present in dried physiological samples
KR102179032B1 (ko) * 2019-09-20 2020-11-18 한림대학교 산학협력단 급성허혈성뇌손상 및 급성외상성뇌손상을 구별하기 위한 바이오마커 및 이의 이용
CN115066616A (zh) * 2020-02-10 2022-09-16 私募蛋白质体操作有限公司 非酒精性脂肪性肝炎(nash)生物标志物及其用途
US20240003918A1 (en) 2020-11-30 2024-01-04 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
CN116879564A (zh) * 2023-09-06 2023-10-13 暨南大学附属第一医院（广州华侨医院） 基于蛋白质组学及磷酸化蛋白质修饰组学的脊髓损伤生物标志物及其应用

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4702909A (en) 1982-05-05 1987-10-27 Louisiana State University A & M Non-A, non-B hepatitis antigen, antigen compositions, vaccine and diagnostic reagent
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US5118606A (en) 1988-09-02 1992-06-02 The Regents Of The University Of California Methods for detecting cellular pathology by assaying spectrin and spectrin breakdown products
US5234814A (en) 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
US5118937A (en) 1989-08-22 1992-06-02 Finnigan Mat Gmbh Process and device for the laser desorption of an analyte molecular ions, especially of biomolecules
US5045694A (en) 1989-09-27 1991-09-03 The Rockefeller University Instrument and method for the laser desorption of ions in mass spectrometry
JPH05506777A (ja) 1990-03-05 1993-10-07 セファロン、インコーポレーテッド キモトリプシン様プロテアーゼ及びそれらの阻害剤
US5586226A (en) 1990-05-16 1996-12-17 Canon Kabushiki Kaisha Control method and device for a unicolor printer
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
ATE160821T1 (de) 1990-06-11 1997-12-15 Nexstar Pharmaceuticals Inc Nukleinsäureliganden
US5252463A (en) 1990-06-22 1993-10-12 The Du Pont Merck Pharmaceutical Company Clipsin, a chymotrypsin-like protease and method of using same
WO1993003369A1 (en) 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
ATE427493T1 (de) 1992-05-29 2009-04-15 Univ Rockefeller Verfahren zur bestimmung der folge von peptiden unter verwendung eines massenspektrometers
US5792664A (en) 1992-05-29 1998-08-11 The Rockefeller University Methods for producing and analyzing biopolymer ladders
EP0700521B1 (en) 1993-05-28 2003-06-04 Baylor College Of Medicine Method and mass spectrometer for desorption and ionization of analytes
DE4337654C2 (de) 1993-11-04 1996-08-08 Biotest Pharma Gmbh Verwendung boviner Kolostralmilch von nicht mit Viren hyperimmunisierten Tieren als Leberschutzpräparat
US5536639A (en) 1994-03-25 1996-07-16 Cephalon, Inc. Methods for detecting calpain activation by detection of calpain activated spectrin breakdown products
ES2222465T3 (es) * 1994-07-15 2005-02-01 Cephalon, Inc. Calpaina activa expresada por baculovirus.
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5777194A (en) * 1995-04-26 1998-07-07 Cephalon, Inc. Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
DE69635979T2 (de) 1996-02-02 2006-11-16 Biotrin Intellectual Properties Ltd., Mount Merrion Verfahren zur bestimmung des hepatischen zustands eines lebertransplantationsempfängers.
US6048703A (en) 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
CN1282242A (zh) 1997-12-16 2001-01-31 赛福伦公司 多相催化蛋白酶抑制剂用作抗肿瘤剂
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
CN1325491A (zh) 1998-09-08 2001-12-05 基因创新有限公司 作为早期CNS损伤标记物的τ
WO2000056934A1 (en) 1999-03-24 2000-09-28 Packard Bioscience Company Continuous porous matrix arrays
US6218005B1 (en) * 1999-04-01 2001-04-17 3M Innovative Properties Company Tapes for heat sealing substrates
US20020002270A1 (en) 1999-06-16 2002-01-03 Raymond P. Zinkowski Purified antigen for alzheimer's disease, and methods of obtaining and using same
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
US6664442B2 (en) * 2000-03-30 2003-12-16 Elan Pharmaceuticals, Inc. Selecting compounds to reduce inflammation associated with Alzheimer's disease
US20050063942A1 (en) 2001-02-02 2005-03-24 Clark Mike A. Methods for predicting sensitivity of tumors to arginine deprivation
US6949377B2 (en) 2001-03-05 2005-09-27 Ho Winston Z Chemiluminescence-based microfluidic biochip
US20040203083A1 (en) 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US20030199000A1 (en) 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20020172676A1 (en) 2001-05-16 2002-11-21 George Jackowski Method of treatment of alzheimer's disease and device therefor
US7144708B2 (en) 2001-06-25 2006-12-05 The Cleveland Clinic Foundation Markers of blood barrier disruption and methods of using same
JP2003070498A (ja) 2001-07-19 2003-03-11 Pharma Design Inc ユビキチンカルボキシルターミナルヒドロラーゼｌ１遺伝子異常の検出方法
JP2005522669A (ja) * 2001-08-20 2005-07-28 バイオサイト インコーポレイテッド 卒中および脳損傷の診断マーカーおよびその使用方法
US20030040660A1 (en) 2001-08-27 2003-02-27 George Jackowski Method for diagnosing and distinguishing traumatic brain injury and diagnostic devices for use therein
AU2002329570A1 (en) * 2001-10-12 2003-01-30 Pfizer Products Inc. Method of monitoring neuroprotective treatment
WO2003062824A1 (en) 2002-01-23 2003-07-31 Boditech Inc. Lateral flow quantitative assay method and strip and laser-induced fluoerescence detection device therefor
EP1476747A4 (en) 2002-01-31 2008-06-11 Ocimum Biosolutions Inc MOLECULAR HEPATOTOXICOLOGICAL MODELING
US20040076974A1 (en) 2002-04-01 2004-04-22 Kier Larry D. Liver necrosis predictive genes
EP1551450A4 (en) 2002-06-12 2005-11-23 Cleveland Clinic Foundation MARKER FOR THE PERMEABILITY OF THE BLOOD BARRIER AND METHOD FOR THEIR USE
EP2211176A3 (en) * 2002-09-11 2010-12-08 University Of Florida Analyzing nerve cell damage
WO2004059293A2 (en) 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
CA2542232A1 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals, Inc. Method for treating neurodegenerative disease by inhibiting alpha-synuclein
JP5019878B2 (ja) 2003-09-20 2012-09-05 エレクトロフォレティックス リミテッド 脳障害関連疾患の診断のためのマーカーの検出に関する方法
GB0322063D0 (en) * 2003-09-20 2003-10-22 Univ Geneve Diagnostic method for brain damage-related disorders
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
US20050130226A1 (en) 2003-09-26 2005-06-16 The University Of Cincinnati Fully integrated protein lab-on-a-chip with smart microfluidics for spot array generation
JP4796967B2 (ja) 2003-11-07 2011-10-19 ヴァーミリオン インコーポレイテッド アルツハイマー病のためのバイオマーカー
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
US20050112585A1 (en) 2003-11-21 2005-05-26 Dominic Zichi Method for adjusting the quantification range of individual analytes in a multiplexed assay
TWI281473B (en) 2003-12-19 2007-05-21 Ind Tech Res Inst Biomarkers for liver diseases and method for using same
AU2004312893B2 (en) 2003-12-31 2010-06-17 President And Fellows Of Harvard College Assay device and method
AU2005238446B2 (en) * 2004-04-15 2009-07-30 Banyan Biomarkers Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US20140303041A1 (en) 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
ES2367311T3 (es) 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US20060292558A1 (en) 2004-07-19 2006-12-28 Cell Biosciences Inc. Methods and apparatus for protein assay diagnostics
WO2006042734A1 (de) 2004-10-15 2006-04-27 Siemens Aktiengesellschaft Verfahren zur durchführung einer elektrochemischen messung an einer flüssigen messprobe in einer über leitungen zugänglichen messkammer und zugehörige anordnung
CA2635198C (en) 2005-04-01 2019-11-12 University Of Florida Research Foundation, Inc Biomarkers of liver injury
US8048638B2 (en) 2005-04-01 2011-11-01 University Of Florida Research Foundation, Inc. Biomarkers of liver injury
GB2428240A (en) 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
WO2007033385A2 (en) 2005-09-13 2007-03-22 Fluidigm Corporation Microfluidic assay devices and methods
WO2007046811A2 (en) 2005-10-20 2007-04-26 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
CA2636508A1 (en) 2006-01-12 2007-07-19 Micah James Atkin New instrumentation systems and methods
US8563291B2 (en) 2006-02-15 2013-10-22 Mie University Method of constructing recombinant proteoliposome for diagnostic use
US20070255113A1 (en) 2006-05-01 2007-11-01 Grimes F R Methods and apparatus for identifying disease status using biomarkers
WO2007136617A2 (en) 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
WO2007140188A2 (en) 2006-05-26 2007-12-06 Biosite Incorporated Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases
WO2008008819A2 (en) 2006-07-11 2008-01-17 University Of Florida Research Foundation, Inc. Diagnosis and treatment of neurological inflammation
AU2007322252A1 (en) 2006-11-01 2008-05-29 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
WO2008097618A1 (en) 2007-02-06 2008-08-14 University Of Florida Research Foundation, Inc. Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
US20120196307A1 (en) 2007-02-06 2012-08-02 Banyan Biomarkers, Inc. Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
CA2715248A1 (en) 2008-02-04 2009-08-13 Banyan Biomarkers, Inc. Process to diagnose or treat brain injury
AU2009236057B2 (en) 2008-04-17 2015-05-07 Banyan Biomarkers, Inc. An antibody bound synthetic vesicle containing active agent molecules
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20140342381A1 (en) 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
NO2324360T3 (cs) 2008-08-11 2018-06-30
US8642558B2 (en) 2008-09-19 2014-02-04 Henry Ford Health Systems Methods, systems, and compositions for calpain inhabition
WO2010059242A2 (en) 2008-11-21 2010-05-27 The Johns Hopkins University Neurodegenerative disease diagnostic compositions and methods of use
US20170315136A9 (en) 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
WO2010148391A2 (en) 2009-06-19 2010-12-23 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
US20120202231A1 (en) 2009-07-18 2012-08-09 Kevin Ka-Wang Wang Synergistic biomarker assay of neurological condition using s-100b
US20130022982A1 (en) 2009-09-14 2013-01-24 Kevin Ka-Wang Wang Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
ES2735530T3 (es) 2010-01-26 2019-12-19 Bioregency Inc Composiciones y métodos relacionados con la argininosuccinato sintetasa
US20130029362A1 (en) 2010-04-01 2013-01-31 Andreas Jeromin Markers and assays for detection of neurotoxicity
WO2011160096A2 (en) 2010-06-17 2011-12-22 Banyan Biomarkers, Inc. Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
WO2012051519A2 (en) 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
WO2013040502A2 (en) 2011-09-14 2013-03-21 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Processes and kits to detect and monitor for diagnostic biomarkers for post traumatic stress disorder (ptsd) and to differentiate between suicidal and non-suicidal form of the disorder
US20140018299A1 (en) 2012-07-10 2014-01-16 Banyan Biomarkers, Inc. Method and device to detect, monitor and promote neural regeneration and improvement of cognitive function in a subject suffering from neural injury
US20140024053A1 (en) 2012-07-20 2014-01-23 Banyan Biomarkers, Inc. Methods, kits and devices for detecting bii-spectrin, and breakdown products thereof, as biomarkers for the diagnosis of neural injury
US20140275294A1 (en) 2013-03-15 2014-09-18 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of liver injury
US20150141528A1 (en) 2013-05-31 2015-05-21 Banyan Biomarkers, Inc. Neural specific s100b for biomarker assays and devices for detection of a neurological condition
EP3129780A4 (en) 2014-04-07 2017-12-13 Iron Horse Diagnostics Inc. Traumatic brain injury and neurodegenerative biomarkers, methods, and systems
AU2015243926A1 (en) 2014-04-08 2016-11-24 The Research Foundation For The State University Of New York Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system
US11078298B2 (en) 2016-10-28 2021-08-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
AU2018250688B2 (en) * 2017-04-15 2024-07-04 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
JP7080899B2 (ja) * 2017-04-28 2022-06-06 アボット・ラボラトリーズ 同じヒト対象に由来する少なくとも２つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
JP7269183B2 (ja) * 2017-05-30 2023-05-08 アボット・ラボラトリーズ 心臓トロポニンｉを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法
AU2018378971B9 (en) * 2017-12-09 2025-04-17 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase l1 (UCH-L1)
WO2019112860A1 (en) * 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1

Also Published As

Publication number Publication date
CA2733990C (en) 2018-12-11
JP5976732B2 (ja) 2016-08-24
JP5781436B2 (ja) 2015-09-24
WO2010019553A3 (en) 2010-07-08
JP2012500388A (ja) 2012-01-05
CA2733990A1 (en) 2010-02-18
AU2009282117B2 (en) 2016-05-12
EP2324360A4 (en) 2012-08-29
US11994522B2 (en) 2024-05-28
EP2324360A2 (en) 2011-05-25
EP3336551B1 (en) 2023-05-31
DK2324360T3 (en) 2018-05-14
ES2665245T3 (es) 2018-04-25
EP2324360B1 (en) 2018-01-31
AU2009282117A1 (en) 2010-02-18
WO2010019553A2 (en) 2010-02-18
US20180031577A1 (en) 2018-02-01
JP2014199262A (ja) 2014-10-23
US20210011028A1 (en) 2021-01-14
US20110143375A1 (en) 2011-06-16
EP3336551A1 (en) 2018-06-20
EP4235181A2 (en) 2023-08-30
EP4235181A3 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
BRPI0909040A2 (cs)
BRPI0917573A2 (cs)
BRPI0908549B8 (cs)
BRPI0918697A2 (cs)
BRPI0917525A2 (cs)
BRPI0920750A2 (cs)
BRPI0919470A2 (cs)
BRPI0922455A2 (cs)
BRPI0907698A2 (cs)
BRPI0923734A2 (cs)
BRPI0917618A8 (cs)
BRPI0912727A2 (cs)
BRPI0922669A2 (cs)
BRPI0908285A2 (cs)
BRPI0910485A2 (cs)
BRPI0914750A2 (cs)
BRPI0908120A2 (cs)
BRPI0915616A2 (cs)
BRPI0919811A2 (cs)
BRPI0912462A2 (cs)
BRPI0904541A8 (cs)
BRPI0920914A2 (cs)
BRPI0922550A2 (cs)
BRPI0916284A2 (cs)
BRPI0911617A2 (cs)